Albany, NY (PRWEB) August 24, 2013
In the wake of China's economic growth and enhanced disease prevention awareness, Chinese human vaccine market has been expanding. In 2012, Chinese human vaccine market valued RMB10.5 billion with the lot release quantity of roughly 773 million person-portions. Restricted by China's national conditions and policies, EPI vaccines still prevail in China and Chinese EPI vaccine market is almost monopolized by state-run enterprises represented by CNBG Tiantan Biological, Biological Products Institutes in Changchun, Chengdu, Wuhan, Shanghai and Lanzhou, and Institute of Medical Biology of Chinese Academy of Medical Sciences in Kunming. In 2012, state-owned enterprises seized 81.5% of the vaccine lot release quantity in Chinese EPI vaccine market.
To check out the complete table of contents, visit: http://www.marketresearchreports.biz/analysis-details/china-human-vaccine-industry-report-2012-2015 .
However, along with the gradual relaxed access to the vaccine market, private companies have sprung up in the Extra EPI vaccine market and acquired more market share. Meanwhile, foreign counterparts occupy considerable market share by virtue of their technological and product advantages. In 2012, private and foreign-funded enterprises occupied 49.9% and 22.1% (by lot release quantity) of Chinese Extra EPI vaccine market respectively. As for human rabies vaccine and varicella vaccine markets, they mastered more than 85% of each.
In recent years, China has made some achievements in overseas vaccine markets. In 2011-2012, China’s annual human vaccine export volume remained over 9,000 tons (9,840 tons in 2010 was subject to the accidental H1N1 flu event), far more than 8,110 tons in 2009. Moreover, many domestic vaccine companies are still planning overseas markets aggressively.
By the end of 2012, the first batch of Hib vaccine products of Walvax Biotechnology were approved by China Customs and exported to Manila, Philippines for official marketing. Walvax Biotechnology is promoting the product registration in Russia, India, Thailand and other countries. In November 2012, Hualan Biological Engineering mailed three consecutive batches of samples for influenza virus split vaccine to WHO for testing. The company is expected to receive WHO’s spot verification certification in 2013. On March 7, 2013, Tiantan Biological obtained the production approval for polio attenuated live vaccine (liquid OPV). In accordance with the cooperation agreement with Bill & Melinda Gates Foundation in 2011, Tiantan Biological will supply OPV to United Nations International Children’s Emergency Fund (UNICEF) formally.
Browse all reports of this category visit - http://www.marketresearchreports.biz/category/79 .
In addition, it is worth mentioning that the industrialization of the world's first recombinant hepatitis E vaccine (Escherichia coli) developed by Xiamen University and YangShengTang INNOVAX jointly was realized on October 27, 2012. As of the end of 2012, the lot release quantity of the product hit 90,000 person-portions.
China Human Vaccine Industry Report, 2012-2015 mainly contains the following aspects:
- Operating environment, status quo, market supply and demand, competition pattern and development prospects of human vaccine in China;
- Market supply and demand, competition patterns, market prices and development trends of 10 kinds of products including hepatitis B vaccine, influenza vaccine, Hib vaccine, human rabies vaccine and pneumococcal vaccine in China;
- Import & export volume and value as well as import sources & export destinations of human vaccine in China;
- 20120114.gif?Operation, revenue structure, vaccine business and development trends of 11 Chinese vaccine enterprises including Tiantan Biological, Hualan Biological Engineering, Zhifei Biological, Walvax Biotechnology and Sinovac Biotech.
Browse all the report of this publisher, visit: http://www.marketresearchreports.biz/publisher/67 .
TABLE OF CONTENT
1. Overview of Vaccine Industry
1.1 Definition & Classification
1.2 Industry Chain
2. Overview of China Human Vaccine Industry
2.2 Operating Environment
2.2.1 International Market
2.2.3 Chinese Biopharmaceutical Market
2.3 Status Quo
2.4 Supply & Demand
2.5 Competition Pattern
2.7 Sales Channel
3. Human Vaccine Market Segments in China
3.1 Hepatitis B Vaccine
3.1.1 Supply & Demand
3.1.2 Competition Pattern
3.1.3 Market Price
3.2 Meningococcal Vaccine
3.2.1 Supply & Demand
3.2.2 Competition Pattern
3.2.3 Market Price
3.2.4 Market Forecast
3.3 Hepatitis A Vaccine
3.3.1 Supply & Demand
3.3.2 Competition Pattern
3.3.3 Market Price
3.3.4 Market Forecast
3.4 Influenza Vaccine
3.4.1 Supply & Demand
3.4.2 Competition Pattern
3.4.3 Market Price
3.5 Hib Vaccine
3.5.1 Supply & Demand
3.5.2 Competition Pattern
3.5.3 Market Price
3.5.4 Market Forecast
3.6 Human Rabies Vaccine
3.6.1 Supply & Demand
3.6.2 Competition Pattern
3.6.3 Market Price
3.6.4 Market Forecast
3.7 Varicella Vaccine
3.7.1 Supply & Demand
3.7.2 Competition Pattern
3.7.3 Market Price
3.8 Pneumococcal Vaccine
3.8.1 Supply & Demand
3.8.2 Competition Pattern
3.8.3 Market Price
3.9 DPT Vaccine
3.9.1 Supply & Demand
3.9.2 Competition Pattern
3.9.3 Market Situation & Forecast
3.10 Poliomyelitis Vaccine
3.10.1 Supply & Demand
3.10.2 Competition Pattern
4. Human Vaccine Import and Export in China
4.1.1 Export Volume and Value
4.1.2 Export Destinations
4.2.1 Import Volume and Value
4.2.2 Import Sources
To buy the copy of this report, visit: http://www.marketresearchreports.biz/analysis/173350 .
5. Major Human Vaccine Producers in China
5.1 China National Biotec Group
5.1.1 Beijing Tiantan Biological Products Co., Ltd.
5.2 Hualan Biological Engineering Inc.
5.2.3 Revenue Structure
5.2.4 Gross Margin
5.2.5 Clients and Suppliers
5.2.6 R&D and Investment
5.2.7 Vaccine Business
5.2.8 Outlook and Forecast
5.3 Chongqing Zhifei Biological Products Co., Ltd.
5.3.3 Revenue Structure
5.3.4 Gross Margin
5.3.6 R&D and Investment
5.3.7 Outlook and Forecast
5.4 Yunnan Walvax Biotechnology Co., Ltd.
5.4.3 Revenue Structure
5.4.4 Gross Margin
5.4.5 Clients and Suppliers
5.4.6 R&D and Investment
5.4.7 Outlook and Forecast
5.5 Sinovac Biotech Ltd.
5.5.3 Revenue Structure
5.5.4 R&D and Investment
5.6 Liaoning Chengda Co., Ltd.
5.6.3 Revenue Structure
5.6.4 Gross Margin
5.6.6 Vaccine Business
5.7 Changchun BCHT Biotechnology Co. Ltd.
5.8 Changchun Changsheng Life Sciences Limited
5.9 Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.
5.10 Shenzhen Kangtai Biological Products Co. Ltd.
5.11 Dalian Hissen Bio-Pharm Co., Ltd.
Global Human Vaccines Market 2011-2015
Global Human Vaccines market to reach US$57.6 billion by 2015. One of the key factors contributing to this market growth is the increase in demand for vaccination against communicable diseases. The Global Human Vaccines market has also been witnessing the increase in awareness programs worldwide. However, emergence of vaccine-resistant viruses could pose a challenge to the growth of this market.
TechNavio's report, the Global Human Vaccines Market 2011-2015, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Human Vaccines market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Emerging Cancer Vaccines Market to 2017 - Novel, First-In-Class Vaccines in Phase II and Phase III Pipeline to Shape the Future Cancer Vaccines Market
GBI Research, the leading business intelligence provider, has released its latest research, Emerging Cancer Vaccines Market to 2017 - Novel, First-In-Class Vaccines in Phase II and Phase III Pipeline to Shape the Future Cancer Vaccines Market, which provides insights into the global emerging cancer vaccines market and a market forecast until 2017. The report provides an in-depth analysis of the five therapeutic indications for which vaccines are available in the market or which have a promising vaccine in Phase III of their pipeline.
90 Sate Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-997-4948